METHOD FOR TREATING TYPE 1 DIABETES

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

METHOD FOR TREATING TYPE 1 DIABETES

Ofer Mandelboim (Inventor), Angel Porgador (Inventor), Yaakov Naparstek (Inventor), Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology and Immunology

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	English
Patent number	US2013280209
IPC	A61K 39/ 395 A I
Priority date	15/04/13
State	Published - 24 Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{c6d54c0ae413409c844a142b083dfbd7,

title = "METHOD FOR TREATING TYPE 1 DIABETES",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

year = "2013",

month = oct,

day = "24",

language = "English",

type = "Patent",

note = "US2013280209; A61K 39/ 395 A I",

}

TY - PAT

T1 - METHOD FOR TREATING TYPE 1 DIABETES

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

PY - 2013/10/24

Y1 - 2013/10/24

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - US2013280209

ER -

METHOD FOR TREATING TYPE 1 DIABETES

Abstract

UN SDGs

Fingerprint

Cite this